Drugs / Q-122
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04080297 | Jan → Jul 2014 | — | Que Oncology | Completed | No outcome recorded |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT03518138 | Oct 2018 → Jul 2020 | — | Que Oncology | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Q-122 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03518138 ↗ |
| Route | Oral | “oral capsule of Q-122” NCT03518138 ↗ |